Charles A. Deignan
2023
In 2023, Charles A. Deignan earned a total compensation of $854.4K as Chief Financial Officer at Clearside Biomedical, a 2% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $148,876 |
|---|---|
| Option Awards | $285,730 |
| Salary | $409,000 |
| Other | $10,800 |
| Total | $854,406 |
Deignan received $409K in salary, accounting for 48% of the total pay in 2023.
Deignan also received $148.9K in non-equity incentive plan, $285.7K in option awards and $10.8K in other compensation.
Rankings
In 2023, Charles A. Deignan's compensation ranked 1,390th out of 3,006 executives tracked by ExecPay. In other words, Deignan earned more than 53.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,390 out of 3,006 | 54th |
Division Manufacturing | 829 out of 1,650 | 50th |
Major group Chemicals And Allied Products | 546 out of 918 | 41st |
Industry group Drugs | 533 out of 881 | 40th |
Industry Pharmaceutical Preparations | 372 out of 637 | 42nd |
Source: SEC filing on April 26, 2024.
Deignan's colleagues
We found two more compensation records of executives who worked with Charles A. Deignan at Clearside Biomedical in 2023.
News
Clearside Biomedical CEO George Lasezkay's 2023 pay stays at $1.5M
April 26, 2024
Clearside Biomedical CEO George Lasezkay's 2022 pay falls 35% to $1.5M
April 28, 2023
Clearside Biomedical President and Chief Executive Office George Lasezkay's 2021 pay jumps 71% to $2.3M
April 29, 2022
Clearside Biomedical Chief Commercial Officer Brion Raymond receives $954K in 2018
April 26, 2019